Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Informatics

Verge Genomics raises $32 million for machine learning-backed neuroscience drug discovery

by Ryan Cross
July 20, 2018 | A version of this story appeared in Volume 96, Issue 30

 

San Francisco-based Verge Genomics has raised $32 million in series A financing to use machine learning for neuroscience drug discovery. The financing was led by DFJ, a venture capital firm better known for its investments in Skype, SpaceX, and Tesla. Verge was founded and is currently helmed by 29-year-old Alice Zhang to tap artificial intelligence to find drugs that target genes involved in neurodegenerative diseases, including Alzheimer’s. The start-up claims partnerships with two undisclosed drug companies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.